A Multicenter and Observational Study to Assess the Effectiveness of Infliximab Comparing With Conventional Therapy in Ankylosing Spondylitis Subjects With Hip Involvement
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 16 Jun 2017
At a glance
- Drugs Infliximab (Primary) ; Disease-modifying antirheumatics; Nonsteroidal anti-inflammatories
- Indications Ankylosing spondylitis
- Focus Therapeutic Use
- Acronyms RECOVERY
- Sponsors Janssen Research & Development
- 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Jun 2017 Biomarkers information updated
- 19 Apr 2017 Planned End Date changed from 13 Apr 2018 to 15 Jan 2018.